Humana Inc. (NYSE: HUM) saw its shares decline approximately 8% in premarket trading Wednesday, as the health insurer's decision to maintain its full-year adjusted EPS floor at $9 overshadowed a robust second-quarter performance. The market reaction reflects investor concerns over the steep implied second-half loss, a stark contrast to the strong first-half results.
Earnings Bridge Raises Red Flags
The company reported adjusted EPS of $17.91 for the first six months of the year, representing 199% of its annual minimum guidance. With the full-year floor set at $9, preliminary calculations suggest an $8.91 adjusted loss per share in the second half. This earnings bridge has become the central focus for analysts, as it implies an unusually severe back-end weighting of expenses.
Morningstar analyst Julie Utterback noted that shareholders had been hoping for a significant upward revision to expectations, similar to what UnitedHealth Group (NYSE: UNH) delivered earlier this month. UNH raised its 2026 adjusted EPS forecast to $19.50-$20, amplifying the disappointment for Humana investors.
Q2 Performance Exceeds Expectations
Despite the cautious outlook, Humana's second-quarter results were solid. Adjusted earnings per share rose 21% year-over-year to $7.61, surpassing the LSEG consensus estimate of $7.22. Revenue grew 26.2% to $40.87 billion, topping the $40.61 billion analysts had projected.
The insurance benefit ratio came in at 91.2%, closely aligning with the 91.19% LSEG forecast, though up from 89.9% in the same period last year. The company offset the higher medical costs through a 120-basis-point reduction in its insurance operating-cost ratio, which fell to 7.1%.
Medical Cost Trends and Enrollment Growth
Management attributed the year-over-year rise in the benefit ratio to three primary factors: Star-rating pressure, the composition of new members, and less favorable reserve development. Medical and pharmacy trends remained in the high single-digit range, with inpatient costs modestly better, particularly for members in value-based provider arrangements.
Enrollment continued to climb rapidly. Individual Medicare Advantage membership increased by 1.204 million, or 23%, as of June. The company maintains its projection of approximately 25% growth for the full year.
Management Commentary and Guidance
Chief Executive Jim Rechtin stated during the earnings call that the first half "went well" and that Humana was "right where we said we'd be." The company forecasts an adjusted loss per share of about $1 for the third quarter. Management noted that second-quarter results accounted for 80% to 85% of the year's adjusted earnings.
Humana lowered its minimum GAAP EPS guidance to $6.52 from $8.36. The company continues to target a sustainable pretax margin of no less than 3% by 2028.
Concentration of Risks Ahead
Several challenges loom for the remainder of the year. Humana projects its insurance benefit ratio will exceed 94% in the third quarter. Ongoing pressure on Star-rating bonuses and the planned discontinuation of the CMS standalone Part D premium-stabilization demonstration after 2026 add to the uncertainty. Humana's Part D membership has surged 50% year-to-date.
Investors will closely monitor third-quarter utilization trends, the finalized Medicare plan landscape in September, and the company's investor update scheduled for December 10.
